A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients

Journal of Chromatographic Science

Volumn 49, Issue 10, 2011, Pages 753-757

  Pirro, Elisa ^a   De Francia, Silvia ^a   De Martino, Francesca ^a   Fava, Carmen ^a   Ulisciani, Stefano ^a   Cambrin, Giovanna Rege ^a   Racca, Silvia ^a   Saglio, Giuseppe ^a   Di Carlo, Francesco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81455139201     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chrsci/49.10.753     Document Type: Article

References (28)

1. C.L. Sawyers. Chronic myeloid leukemia. N. Engl. J. Med. 340: 1330-1340 (1999). (Pubitemid 29196596)
2. B.J. Drucker,M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S.Ohno-Jones, and C.L. Sawyers. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J.Med. 344: 1031-1037 (2001). (Pubitemid 32267972)
3. R. Bakhtiar, L. Khemani, M. Hayes, T. Bedman, and F. Tse. Quantification of the antileukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 28: 1183-1194 (2002). (Pubitemid 34607403)
4. B.J. Druker. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91: 1-30 (2004). (Pubitemid 39140955)
5. N.P. Shah and C.L. Sawyers. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 22: 7389-7395 (2003). (Pubitemid 37487164)
6. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and C.L. Sawyers. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplication. Science. 293: 876-880 (2001). (Pubitemid 32743979)
7. J. Cortes, E. Jabbour, H. Kantarjian, C.C. Yin, J. Shan, S. O'Brien, G. Garcia- Manero, F. Giles, M. Breeden, N. Reeves,W.G.Wierda, and D. Jones. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 110: 4005-4011 (2007). (Pubitemid 350248456)
8. L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, K. Behnia, S. Castaneda, L.A. Cornelius, J.Das, A.M.Doweyko, C. Fairchild, J.T.Hunt, I. Inigo, K. Johnston, A. Kamath,D. Kan,H. Klei, P.Marathe, S. Pang, R. Peterson, S. Pitt,G.L. Schieven, R.J. Schmidt, J. Tokarski,MLWen, J.Wityak, and R.M. Borzilleri. Discovery of N- (2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J.Med. Chem. 47: 6658-6661 (2004). (Pubitemid 40053752)
9. A.V. Kamath, J. Wang, F.Y. Lee, and P.H. Marathe. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 61: 365-376 (2008). (Pubitemid 350275972)
10. M.C. Frame. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta. 1602: 114-130 (2002). (Pubitemid 34521791)
11. E.Weisberg, P.W.Manley,W. Breitenstein, J. Brüggen, S.W. Cowan-Jacob, A. Ray, B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, A.L. Kung, J. Mestan, G.Q. Daley, L. Callahan, L. Catley, C. Cavazza, M. Azam, D. Neuberg, R.D. Wright, D.G. Gilliland, and J.D. Griffin. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 7: 129-141 (2005). (Pubitemid 40248339)
12. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, K. Bochinski, A. Hochhaus, J.D. Griffin,D.Hoelzer,M. Albitar,M.Dugan, J. Cortes, L. Alland, andO.G.Ottmann. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J.Med. 354: 2542-2551 (2006). (Pubitemid 43882350)
13. R. Bakhtiar, J. Lohne, L. Ramos, L. Khemani, M. Hayes, and F. Tse. Highthroughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatographytandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 768: 325-340 (2002). (Pubitemid 34158868)
14. K. Titier, S. Picard, D. Ducint, E. Teilhet, N. Moore, P. Berthaud, F.X. Mahon, and M. Molimard. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 27: 634-640 (2005). (Pubitemid 41437643)
15. B. Rochat, A. Fayet, N. Widmer, S.L. Lahrichi, B. Pesse, L.A. Décosterd, and J. Biollaz. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J.Mass Spectrom. 43: 736-752 (2008). (Pubitemid 351954808)
16. T. Velpandian, R. Mathur, N.K. Agarwal, B. Arora, L. Kumar, and S.K. Gupta. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 804: 431-434 (2004). (Pubitemid 38481720)
17. N. Widmer, A. Beguin, B. Rochat, T. Buclin, T. Kovacsovics, M.A. Duchosal, S. Leyvraz, A. Rosselet, J. Biollaz, and L.A. Decosterd. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography- ultraviolet absorbance detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803: 285-292 (2004). (Pubitemid 38455451)
18. E. Schleyer, S. Pursche, C.H. Kohne, U. Schuler, U. Renner, H. Gschaidmeier, J. Freiberg-Richter, T. Leopold, A. Jenke, M. Bonin, T. Bergemann, P. le Coutre, M. Gruner, M. Bornhäuser, O.G. Ottmann, G. Ehninger. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite Ndesmethyl- STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 799: 23-36 (2004). (Pubitemid 37500860)
19. G. Guetens, H. Prenen, G. De Boeck, Allan van Oosterom, P. Schoffski, M. Highley, E. A. de Bruijn. Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 846: 341-345 (2007). (Pubitemid 46149485)
20. S. Pursche, O.G. Ottmann, G. Ehninger, E. Schleyer. High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culturemediumand cell preparations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852: 208-216 (2007). (Pubitemid 46830984)
21. F.R. Luo, Y.C. Barrett, Z. Yang, A. Camuso, K. McGlinchey, M. Wen, R. Smykla, K. Fager, R. Wild, H. Palme, S. Galbraith, A. Blackwood-Chirchir, and F.Y. Lee. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCELTM), a multi-targeted kinase inhibitor. Cancer Chemother. Pharmacol. 62: 1065-1074 (2008).
22. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration (2001).
23. R.L. Oostendorp, J.H. Beijnen, J.H. Schellens, and O. Tellingen. Biomed Chromatogr. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversedphase high-performance liquid chromatography. Biomed. Chromatogr. 21: 747-754 (2007). (Pubitemid 47082252)
24. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. Silver, and R. Hehlmann. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 108: 1809-1820 (2006). (Pubitemid 44394987)
25. L. Alnaim. Therapeutic drug monitoring of cancer chemotherapy. J. Oncol. Pharm. Pract. 13: 207-221 (2007).
26. P. Marquet and A. Rousseau. Pharmacokinetics and therapeutic drug monitoring of anticancer agents. Bull Cancer. 95: 903-909 (2008).
27. B. Peng, M. Hayes, D. Resta, A. Racine-Poon, B.J. Druker, M. Talpaz, C.L. Sawyers, M. Rosamilia, J. Ford, P. Lloyd, and R. Capdeville. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin.Oncol. 22: 935-942 (2004). (Pubitemid 41103606)
28. S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.A. Bernard, R. Lasalle, G.Marit, J. Reiffers, B. Begaud, N.Moore,M.Molimard, and F.X.Mahon. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496-3499 (2007). (Pubitemid 46572540)